Halozyme Therapeutics | HALO - Trade Debtors


Halozyme Therapeutics reported $453.33M in Trade Debtors for its fiscal quarter ending in June of 2026.





Trade Debtors Change Date
Acadia Pharmaceuticals USD 166.33M 17.95M Jun/2026
Agios Pharmaceuticals USD 16.13M 5.56M Mar/2026
Alnylam Pharmaceuticals USD 912.74M 28.78M Jun/2026
Amarin USD 126.83M 477K Dec/2025
Amgen USD 10.23B 1.09B Jun/2026
Baxter International USD 1.86B 158M Jun/2026
Cara Therapeutics USD 2.24M 2.26M Mar/2025
Cytokinetics USD 6.83M 10.94M Mar/2026
DBV Technologies USD 15.1M 1.05M Mar/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Halozyme Therapeutics USD 453.33M 4.66M Jun/2026
Intrexon USD 1.02M 559K Jun/2024
Ionis Pharmaceuticals USD 58.84M 15.16M Jun/2026
MannKind USD 43.21M 15.07M Jun/2026
Nektar Therapeutics USD 3.6M 1.82M Mar/2026
Pfizer USD 16.19B 19M Jun/2026
Rigel Pharmaceuticals USD 28.9M 1.39M Jun/2024
United Therapeutics USD 310.3M 1.7M Jun/2026
Vanda Pharmaceuticals USD 47.1M 4.35M Dec/2024